FLFranco Lori

Franco Lori

*This is an algorithmically generated author record based on publicly available information.

Franco Lori has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Julianna Lisziewicz

    Research Institute for Genetic and Human Therapy (RIGHT), Washington, DC, USA

    18 shared publications
  • Andrea Foli

    Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy

    6 shared publications
  • A. Foli

    2 shared publications
  • David B. Weiner

    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA

    2 shared publications
  • Elisabetta Ravot

    Research Institute for Genetic and Human Therapy (RIGHT) at IRCCS Policlinico S. Matteo Pavia, Italy, and Washington, DC

    2 shared publications
  • Jianqing Xu

    Research Institute for Genetic and Human Therapy (RIGHT) at IRCCS Policlinico S. Matteo Pavia, Italy, and Washington, DC

    2 shared publications

Latest Publications

  • DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS

    by Franco Lori

    The HIV global pandemic continues to rage with over 33 million people living with the disease. Although multidrug therapy has improved the prognosis for those infected by the virus, it has not eradicated the infection. Immunological therapies, including therapeutic vaccines, are needed to supplement drug therapy in the search for a 'functional cure' for HIV. DermaVir (Genetic Immunity Kft, Budapest, Hungary and McLean, Virginia, USA), an experimental HIV/AIDS therapeutic vaccine, combines three key elements of rational therapeutic vaccine design: a single plasmid DNA (pDNA) immunogen expressing 15 HIV antigens, a synthetic pDNA nanomedicine formulation and a dendritic cell-targeting topical-vaccine administration. DermaVir's novel mechanism of action, natural transport by epidermal Langerhans cells to the lymph nodes to express the pDNA-encoded HIV antigens and induce precursor/memory T cells with high proliferation capacity, has been consistently demonstrated in mouse, rabbit, primate and human subjects. Safety, immunogenicity and preliminary efficacy of DermaVir have been clinically demonstrated in HIV-infected human subjects. The DermaVir technology platform for dendritic cell-based therapeutic vaccination might offer a new treatment paradigm for cancer and infectious diseases.


  • IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine

    by Sandra A. Calarota, Anlan Dai, Jeffrey N. Trocio, David B. Weiner, Franco Lori, Julianna Lisziewicz


  • Treating HIV/AIDS by reducing immune system activation: the paradox of immune deficiency and immune hyperactivation

    by Franco Lori

    Purpose of review To collect published evidence in support of a novel immune therapeutic approach to reduce the excess of immune activation that ultimately turns into immune deficiency in HIV/AIDS. Recent findings A large body of evidence has been collected in support of the pathogenetic interpretation that prolonged immune overactivation induced by HIV during the course of chronic infection exhausts the immune system and leads to AIDS. Some groups are exploring the possibility of therapeutic interventions to limit the immune system overload. Cytostatic drugs appear promising candidates to achieve the goal, as they restrain cell proliferation without blocking it. At the same time, they do not affect cellular response to antigenic stimulation, and at appropriate dosages are not immune suppressive. Summary Presently available antiretrovirals only partially reduce immune system activation during chronic HIV infection. Further clinical research is warranted to test cytostatic drugs to avert immune overactivation and prevent progression to AIDS.


  • Open Access

    A Checkpoint in the Cell Cycle Progression as a Therapeutic Target to Inhibit HIV Replication

    by Andrea Foli, Maria Angela Maiocchi, Julianna Lisziewicz, Franco Lori

    Human immunodeficiency virus (HIV) expression is boosted after T lymphocyte stimulation. It is not known, however, in which phase(s) of the cell cycle HIV is maximally expressed.We demonstrate here that cell activation induces limited HIV expression and that progression to cell proliferation is required for optimal HIV replication. We also show that the G1/S cell cycle transition is a critical checkpoint in this process and that limiting progression at this step with antiproliferative drugs suppresses HIV replication. These results identify a specific phase of the cell cycle progression that is critical for HIV expression and suggest a new discrete target for anti-HIV treatment.


  • Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options

    by Franco Lori, Andrea Foli, Julianna Lisziewicz

    Purpose of review To examine the literature in search of data supporting (stopping highly active antiretroviral therapy (HAART) temporarily in the absence of virus rebound) to expand HIV treatment options. Recent findings We proposed investigating HAART interruptions after the ‘Berlin patient’ had discontinued HAART while keeping HIV suppressed. The idea of inducing immune control of HIV by treatment interruptions has been largely abandoned and with clinicians have mainly investigated whether treatment withdrawal can reduce toxicity, improve the quality of patients' lives, and save costs. Some data suggest that treatment interruptions remain a feasible strategy and the benefits outweigh the costs; others warn against several pitfalls: onset of resistance, HIV transmission and increased toxicity. Researchers have also found, however, that the viral set point can be lowered by treatment interruptions during chronic infection, similar to (but to a lesser extent than) acute infection. Preliminary studies suggest that immunomodulators and therapeutic vaccines may further improve immune control of HIV replication. Summary Exposure to HIV leads to excessive immune activation and exhaustion. Viral rebounds should be contained to obtain therapeutic benefits and decrease virus transmission. Temporary interruptions of HAART in combination with therapeutic vaccinations and immune modulators, such as antiproliferative drugs, may suppress HIV for extended periods of time.


  • Virostatics: a new class of anti-HIV drugs.

    by F. Lori, A. Foli, L.M. Kelly, J. Lisziewicz

    Abstract: In this review we discuss the features of a new class of antiretroviral combinations, namely “Virostatics”. Virostatics are characterized by the combination of a drug directly inhibiting virus production (viro), and another drug indirectly inhibiting the virus by reducing cellular proliferation (static). In particular, we will focus on the combination of hydroxyurea and didanosine against HIV-1. Hydroxyurea and didanosine synergize to control viral replication and present with a favorable resistance profile, suppressing several resistant quasi-species. Because virostatics target essential cellular proteins, they exert an immune modulating activity and reduce viral targets (CD4 T cells), possibly with limited immunosuppressive effects. Importantly, a dose-finding clinical study has shown that decreasing the dose of hydroxyurea not only diminishes toxicity but also increases antiviral potency. Therefore, the combination of hydroxyurea and didanosine strikes a balance between viral suppression, drug-related toxicity and viral escape, and could have a role both in induction and maintenance therapy. In this review we would like to appraise what is known about hydroxyurea and didanosine and specifically address the major advantages, i.e. novel mechanism of action leading to a new class of drugs and resistance profile providing durability, as well as the major criticisms of this combination, i.e. toxicity and reasons for prescribing a perceived immune suppressant to immune compromised patients.


  • Cytokine-adjuvanted HIV-DNA vaccination strategies

    by Franco Lori, David B. Weiner, Sandra A. Calarota, Laurene M. Kelly, Julianna Lisziewicz

    This review highlights some of the most common cytokines currently being tested as adjuvants in HIV-1-DNA vaccine regimens. We discuss their use in both the prophylactic and therapeutic setting. Finally, we describe a novel dendritic cell-targeted vaccine candidate for HIV-1 treatment and prevention called DermaVir and explore the combination of the DermaVir technology with the cytokine adjuvants interleukin-7 and interleukin-15.


  • Lowering the Dose of Hydroxyurea Minimizes Toxicity and Maximizes Anti-HIV Potency

    by Franco Lori, R.B. Pollard, L. Whitman, N. Bakare, G. Blick, P. Shalit, A. Foli, D. Peterson, A. Tennenberg, S. Schrader, et al.

    The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea–didanosine combination. In a randomized, open-label study (RIGHT 702, a multicenter trial performed in private and institutional practices), three daily doses (600 µg, 800–900 µg, and 1200 µg) of hydroxyurea were administered in combination with didanosine and stavudine to 115 chronically HIV-infected patients, one-third antiretroviral drug naive, with viremia between 5000 and 200,000 copies/ml regardless of CD4+ cell count. The primary efficacy end point was the proportion of patients with plasma HIV-1 RNA levels below 400 copies/ml after 24 weeks of therapy. In the RIGHT 702 intent-to-treat population the lowest (600 mg) dose of hydroxyurea was better tolerated, associated with fewer adverse events, and more potent by all efficacy parameters, including the primary end point (76 versus 60% patients with viremia < 400 copies/ml at week 24 for the 600-mg and 800- to 900-mg dose groups, respectively; p = 0.027), the mean area under the curve (60.3 versus 65.8; p = 0.016), and the mean log10 decrease (–1.95 versus –0.77; p = 0.001). Patients receiving 600 mg of hydroxyurea daily also had the highest CD4+ cell count, CD4+/CD8+ cell ratio, and lowest CD8+ cell count and percentage (p = 0.035). The RIGHT 702 trial provides an explanation for the increased toxicity and decreased efficacy of hydroxyurea when it was used at high dosage (1200 mg daily). At the optimal dosage of 600 mg daily, hydroxyurea, in combination with didanosine, deserves reevaluation for the long-term management of HIV/AIDS worldwide, because of its excellent resistance profile, durability, and affordability.


  • DermaVir, a novel HIV immunisation technology

    by F Lori, J Trocio, N Bakare, L Kelly, J Lisziewicz